Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1796P - Treatment patterns and survival for small cell lung cancer patients: A nationwide Danish register study

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Small Cell Lung Cancer

Presenters

Anders Green

Citation

Annals of Oncology (2020) 31 (suppl_4): S974-S987. 10.1016/annonc/annonc290

Authors

A. Green1, K.E. Olsen2, G. Persson3, M. Bliddal4, K.K. Andersen5, T. Hallerbäck6, E. Jakobsen7

Author affiliations

  • 1 Open Patient Data Exploratory Network, Institute of Applied Economics and Health Research (ApHER), and Odense University Hospital and University of Southern Denmark, 2200 - Odense/DK
  • 2 Danish Lung Cancer Registry, Department Of Thoracic Surgery, And Department Of Pathology, Odense University Hospital, 5000 - Odense/DK
  • 3 Department Of Oncology And Department Of Clinical Medicine, Herlev Hospital University of Copenhagen, 2730 - Herlev/DK
  • 4 Open Patient Data Exploratory Network, University Southern Denmark, 5000 - Odense/DK
  • 5 Medical Evidence Denmark, AstraZeneca Nordic-Baltic, 2750 - Ballerup/DK
  • 6 Medical Evidence Sweden, AstraZeneca Nordic-Baltic, 15185 - Sodertaelje/SE
  • 7 ) Open Patient Data Exploratory Network, And Danish Lung Cancer Registry, Department Of Thoracic Surgery, Odense University Hospital and University of Southern Denmark, 5000 - Odense C/DK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1796P

Background

Although small cell lung cancer (SCLC) patients usually respond well to first line treatment, long-term survival remains poor. Most patients are diagnosed late with extensive disease (ED), and only limited development of new treatments has been seen over the last decades. Here, we describe treatment patterns for SCLC patients in a real-life setting in Denmark.

Methods

SCLC patients diagnosed in Denmark during 2006-2015 were identified in the Danish Cancer Registry, with follow-up through 2018. Patient- and tumor data were linked to data on co-morbidity, resection, chemoradiotherapy [CRT], radiotherapy only [RT], and chemotherapy only [CT] from the National Patient Registry. Survival was estimated using Kaplan-Meier methods.

Results

During the study period, 6,353 patients were diagnosed with SCLC. Mean age was 68.5 years, 50.8% were male, 37.1% had ≥1 co-morbidity. Overall, 68.2% had ED (stage IV), 25.7% had limited disease (LD; stage I-III), 6.1% had missing information. Death within 60 days from diagnosis, without completing treatment, was reported for 31.1% and 7.9% for ED and LD, respectively. Median survival for ED and LD was 6.2 and 15 months; and the 5-yr survival was 15% for LD and 2% for ED, respectively. Among patients with ED surviving >60 days, 5.4% received no treatment; 0.3% were resected; 3.2% received RT; 73.1% received CT; 17.9% received CRT, and 0.5% had registered prophylactic cranial irradiation (PCI). For LD, 5.3% received no treatment; 4.3% resection; 3.5% RT; 36.9% CT; 50.0% CRT; and 1.3% registered PCI. Median number of CT treatments registered during one year after initiated CT was 8 for both ED and LD. Median number of RTs registered during one year after initiated RT was 4 and 6 for patients with ED and LD, respectively.

Conclusions

Survival of SCLC patients is poor, and many patients die before completing treatment, which highlights a big unmet need for effective therapies. Recent data from clinical trials have shown survival benefit of immunotherapy in combination with chemotherapy in treatment naïve ED SCLC patients. These new treatment strategies may have the potential to improve long-term survival in this severely ill patient population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

AstraZeneca AB.

Funding

AstraZeneca AB.

Disclosure

G. Persson: Speaker Bureau/Expert testimony: AstraZeneca; Speaker Bureau/Expert testimony: BMS; Speaker Bureau/Expert testimony: MSD; Speaker Bureau/Expert testimony: Takeda. K.K. Andersen, T. Hallerbäck: Full/Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.